PDCD1 and cancer: Currently, multiple FDA-approved PD-1-targeting ICIs (pembrolizumab, nivolumab, cemiplimab, dostarlimab, and retifanlimab) or PD-L1-targeting ICIs (atezolizumab, durvalumab, and avelumab) are available for remedying various types of cancer.